Mel Sorensen

Biography

Dr. Sorensen has been President and Chief Executive Officer of Galera Therapeutics since 2012. He is a Medical Oncologist who has spent 7-8 years each in patient care (oncology fellowship at the Mayo Clinic), in academia (Senior Investigator at the National Institutes of Health), and in leadership positions in clinical development in the pharmaceutical industry (Bayer and GlaxoSmithKline).  Since 2004, he has served as President & CEO of private venture-funded biotechs. Dr. Sorensen has raised over $150 million in several private financing rounds and has led licensing deals for multiple preclinical and clinical-stage compounds. He also serves as Chairman of other biotech companies, including Oncopia Therapeutics and OncoFusion Therapeutics, and is an advisor to the Biomarkers Consortium of the National Institutes of Health and to the Irish Cancer Society.     Dr. Sorensen has been President and Chief Executive Officer of Galera Therapeutics since 2012. He is a Medical Oncologist who has spent 7-8 years each in patient care (oncology fellowship at the Mayo Clinic), in academia (Senior Investigator at the National Institutes of Health), and in leadership positions in clinical development in the pharmaceutical industry (Bayer and GlaxoSmithKline).  Since 2004, he has served as President & CEO of private venture-funded biotechs. Dr. Sorensen has raised over $150 million in several private financing rounds and has led licensing deals for multiple preclinical and clinical-stage compounds. He also serves as Chairman of other biotech companies, including Oncopia Therapeutics and OncoFusion Therapeutics, and is an advisor to the Biomarkers Consortium of the National Institutes of Health and to the Irish Cancer Society.    

Research Interest

Host defense mechanisms,LPS effects on neurotransmitters